The overall objective of this proposal is to define the cellular mechanisms responsible for the malignant transformation of biliary epithelia. Since chronic inflammation of the biliary tree predisposes to malignant transformation of cholangiocytes, the long-term goal is to understand the mechanisms by which inflammatory mediators, especially the inducible form of nitric oxide synthase (iNOS), contributes to the development and progression of biliary tract cancers. The central hypothesis is that NO derived from iNOS expression in cholangiocytes promotes the development and progression of cholangiocarcinoma by inhibiting DNA repair and cellular apoptosis via nitrosylation of critical proteins. Using molecular, biochemical, and cell biological approaches, the PI will test this central hypothesis in three specific aims. The first specific aim is to test the hypothesis that NO directly inhibits base excision DNA repair proteins, especially 8-oxodeoxyguanine glycosylase (hOGG1), resulting in potentiation of DNA damage during oxidative stress. The second specific aim is to test the hypothesis that NO inhibits the mitochondrial pathway of apoptosis by directly nitrosylating procaspase 9 rendering cholangiocarcinoma cells resistant to apoptosis-inducing treatments. The third specific aim is to test the hypothesis that iNOS expression enhances tumor progression and metastases in cholangiocarcinoma xenografts and promotes the development and progression of cholangiocarcinoma in an animal model of this disease. Successful completion of these proposed studies has the potential for development of new strategies to prevent and treat malignant human liver diseases.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-SSS-3 (03))
Program Officer
Doo, Edward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Rizvi, Sumera; Gores, Gregory J (2018) Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. Hepatology 68:2428-2430
Yang, Ju Dong; Gores, Gregory J (2018) Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer? Hepatology 68:1217-1219
Kabashima, Ayano; Hirsova, Petra; Bronk, Steven F et al. (2018) Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J Hepatol 68:1228-1238
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Rizvi, Sumera; Fischbach, Samantha R; Bronk, Steven F et al. (2018) YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget 9:5892-5905
Rizvi, Sumera; Khan, Shahid A; Hallemeier, Christopher L et al. (2018) Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95-111
Smoot, Rory L; Werneburg, Nathan W; Sugihara, Takaaki et al. (2018) Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J Cell Biochem 119:824-836
Mertens, Joachim C; Rizvi, Sumera; Gores, Gregory J (2018) Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1454-1460
Loeuillard, Emilien; Fischbach, Samantha R; Gores, Gregory J et al. (2018) Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis :
Rizvi, Sumera; Yang, Ju Dong; Gores, Gregory J (2017) Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 66:4-5

Showing the most recent 10 out of 64 publications